Journal articles on the topic 'Amy Stuart'

A map created from data compiled by Isabela Schettino and Katie Radvany at the Reimagining Education: Teaching and Learning in Racially Diverse Schools Summer Institute (held at Teachers College, Columbia University, and directed by Amy Stuart Wells) shows which states have included references to culturally responsive teaching practices in the ESSA plans submitted to the Department of Education.

Abstract The authors did not submit an updated abstract. The original abstract should be considered final. Citation Format: Eva Segelov, Amy Body, Stuart Turville, Corey Smith, Katie Lineburg, Sudha Rao, Robert McCuaig, Stephen Opat, Zin Niang, Luxi Lal, Vi Luong, Hesham Abdulla, Veronica Aedo Lopez, Bhavna Padhye, Noemi Fuentes Bolanos, Antoinette Anazodo, Raina MacIntyre, Peter Downie, Tracey O'Brien, Elizabeth Ahern. Comprehensive measures of COVID-19 vaccine efficacy in adolescent cancer patients: Results from SerOzNET [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT567.

In this article, Amy Stuart Wells and Irene Serna examine the political struggles associated with detracking reform. Drawing on their three-year study of ten racially and socioeconomically mixed schools that are implementing detracking reform, the authors take us beyond the school walls to better understand the broad social forces that influence detracking reform. They focus specifically on the role of elite parents and how their political and cultural capital enables them to influence and resist efforts to dismantle or lessen tracking in their children's schools. Wells and Serna identify four strategies employed by elite parents to undermine and co-opt reform initiatives designed to alter existing tracking structures. By framing elite parents' actions within the literature on elites and cultural capital, the authors provide a deeper understanding of the barriers educators face in their efforts to detrack schools.

In Amy Tan’s The Bonesetter’s Daughter, Chinese American mother LuLing involves in the self-exploration vacillating between her home and host cultures. The Chinese immigrant LuLing cannot remain totally independent of her indigenous culture of her native country China. Consequently, she demonstrates residual of Chinese culture in her diasporic life. Moreover, she forces her American born daughter to follow the same which sometimes renders conflict in mother-daughter relation. However, she cannot resist the influences of the culture of host country in the United States. She follows certain practices of American cultures. At the same time, she manifests an ambivalent attitude to both cultures. In such cultural interaction, her subjectivity encompasses multiplicities and pluralities by deconstructing the binary of the home and host culture. In this article, the formation of her subjectivity is analyzed through the critical postulations of ‘being’ and ‘becoming’ of Stuart Hall and ‘third space’ of Homi Bhabha. Hall’s representation in Bhabha’s third space can be interpreted and analyzed in the light of Arjun Appadurai’s modernity of cultural globalization. Precisely, the cultural interaction in the third space of the diaspora renders fluid and unstable subjectivity of LuLing which simultaneously belongs to past, present and future.

This article examines the problematic cultural identity of the first-generation immigrants in Amy Tan’s The Bonesetter’s Daughter (2001) and Jhumpa Lahiri’s The Namesake (2003). The immigrant characters problematize their cultural identity by oscillating in the cultural spaces of their home country and the host country. They tend to adopt new cultural identity of their host country while sustaining the old one of their home country. As a result, they negotiate their cultural identity in the shared cultural space which Homi K Bhabha terms as the third space. While analyzing the third space of cultural encounter, I refer to homeland culture as the first and the host land culture as the second cultural space of immigrants. Negotiating in the third space of the diaspora, the immigrants embody fluid and dynamic cultural identities that go beyond the binary of the host and home country. The process of the cultural negotiation of the immigrants is analyzed in the critical frame of Stuart Hall’s cultural identity and Homi Bhabha’s third space in this article.

The relationship in Asian immigrant families ranges from intergenerational and intercultural conflict to mutual understanding over the period of the time. Shaped by different cultural contexts of native and host land, the first and second-generation immigrants have varying world views, perceptions and attitudes rendering conflicts of interests in their priorities. These differences are further widened by their generational differences. However, they negotiate their cultural differences and show mutual understanding, respect for differential priorities and flexibility for co-optation of diverse cultural practices. They involve in dynamic intergenerational relationship full of inconsistencies and contradictions, which keeps of changing in different contexts over the period of time. This article explores the dynamic relationship of the first and second-generation immigrants in Asian-American narratives: The Namesake by Jhumpa Lahiri, The Bonesetter’s Daughter by Amy Tan, Native Speaker by Change rae Lee and Chorus of Mushrooms by Hiromi Goto. Both generation immigrant characters in these narratives constantly vacillate between the cultural spaces of their home and host countries in their negotiation of intergenerational relationship. This article analyzes the cultural vacillation of immigrants in the critical frame of Stuart Hall’s cultural identity which he conceptualizes in his notion of being and becoming.

AbstractBetween 1903 and 1904, the two-step “Hiawatha” spread rapidly throughout much of the colonial world. The travels of “Hiawatha” reveal both what Stuart Hall calls the “double-stake” of popular culture as well as what Amy Kaplan describes as the “anarchic” nature of empire: through its circulation and repeated hearings, “Hiawatha” became both a kind of colonizing force and also a medium that disturbed ideas about racial hierarchies and nationhood that served to justify colonial rule. By charting the global movement of “Hiawatha,” I show how the song became both a colonial force and also a medium for expressions that challenged imperial logic. The tune exhibited imperial tendencies: it saturated soundscapes and, as part of an emerging form of new musical commodities, coaxed listeners into recognizing their shifting status from auditors to consumers. Through its Native American subject matter, the song also helped to perpetuate ideas of evolutionary racial science that served to justify the violence of imperialism. The very qualities that made “Hiawatha” a colonizing song, though, especially its repetitious ubiquity, also increased the complexity of its meaning as it circuited the globe, leading some listeners to hear an accumulation of meanings that seemed to exceed the forms of US imperial pop.

This is the second of three articles on “Sources of Authority in Education”. All use the work of Amy Gutmann as a heuristic device to describe and explain the prevalence of market-based models of Education Reform in the United States as part of what Pasi Sahlberg terms the Global Education Reform Movement (GERM). This movement is based on neoliberal tenets and encourages the enterance of private business and the adoption of business practices and challenges long standing notions of democratic education. The first article is “Negating Amy Gutmann: Deliberative Democracy, Education and Business Influence” (to be published in Democracy and Education) and the third is “The Odd Malaise of Democratic Education and the Inordinate Influence of Business” (to be published in Policy Futures in Education). My intent is to include them, along with a fourth article, “Profit, Innovation and the Cult of the Entrepreneur: Civics and Economic Citizenship,” as chapters of a proposed volume, Democratic Education and Markets: Segmentation, Privatization and Sources of Authority in Education Reform. The “Negating Amy” article looks primarily at Deliberative Democracy. The present article considers the promise of Egalitarian Democracy and how figures such as Horace Mann, John Dewey, and Gutmann have argued it is based largely on the promise of public education. “The Odd Malaise” article begins by offering some historical background, from the origins of the common school in the 1600s to market emulation models, No Child Left Behind and how this is reflected in a “21st century schools” discourse; it ends by considering and underlying theme: what happens to the Philosophy of Education when Democracy and Capitalism are at odds. The “Profit, Innovation” article then looks at how ideological forces are popularized, considering Ayn Rand’s influence, the concept of Merit, Schumpeter’s concept of ‘creative destruction,’ and the ideal of the entrepreneur as related sources in a changing common sense, pointing out that the commonplace of identifying the innovator and the entrepreneur is misplaced. The present article accordingly begins to question business influence and suggest show we may outline its major features using Amy Gutmann’s work as a heuristic device to interpret business-influenced movements to reform public education. Originally the title was Turning Amy Gutmann on her Head. Consequently it returns to Gutmann’s Democratic Education and its three sources of authority, suggesting that the business community is a fourth source. As such, it is in a contest to supplant the systems of deliberative democracy for which Gutmann advocates. It continues with a consideration of what might be called a partial historical materialist analysis – the growth of inequality in the United States (and other countries) since the 1970s; this correlates with much of the basis for changes in the justifications and substance of Education reform. After casting this question in principal-agent terms, it then looks at both those who sought to create a public will for public education and recent reform movements that have sought to redirect public support from a unified education system and instead advocate a patchwork of charters, vouchers for private schools, on-line education, home schooling, virtual schools and public schools based on market emulation models. Drawing from other theories of education, especially Plato (and the Spartan model), Locke, and John Stuart Mill, it also suggests that it might be instructive to compare Gutmann’s three sources of authority to Abraham Kuyper’s concept of Sphere sovereignty. It concludes that ultimate authority for education is —or should be—, somewhat paradoxically, vested in the adult the child will become, creating practical problems regarding the education of the sovereign that are never fully resolved and which may, in fact, be unresolvable based on rational deliberation. Finally, it looks at one instrument of business, market segmentation, and its importance as a motivating factor for education reform.

For the last two-and-a-half years, authors Amy Stuart Wells, Alejandra Lopez, Janelle Scott, and Jennifer Jellison Holme have been engaged with a team of researchers in a comprehensive qualitative study of charter schools in ten California school districts. They have emerged from this study with a new understanding of how the implementation of a specific education policy can reflect much broader social changes, including the transformation from modernity to postmodernity. Given that much of the literature on postmodernity is theoretical in nature, this article invites readers to wrestle with the complexity that results when theory meets the day-to-day experiences of people trying to start schools. In their study, the authors examined how people in different social locations define the possibilities for localized social movements, and how they see the potential threat of greater inequality resulting from this reform within and among communities. They started with a framework that questioned how charter schools came into being at this particular time that is characterized by global economic developments and demands for a more deregulated state education system. This framework allowed the authors to examine the particularistic nature of a reform that defies universal definitions. Their purpose was not to definitively state whether or not charter school reform is "working," or whether or not it is leading to greater social stratification across broad categories of race, class, and gender. Rather, the authors focused on understanding how modern identities and postmodern ideologies converge and, thus, for whom charter school reform is "working," under what conditions, and on whose terms.

Abstract Background: The Myc transcription factor has a short half-life of 20-30 minutes (Ramsay et al. 1984) and oncogenic activation and transcriptional addiction leads to sustained levels of Myc, (Gabay et al. 2014). Mechanisms of activation include MYC gene amplification, mutation or rearrangement and have been reported to be prevalent in gynecologic malignancies, such as serous ovarian (39.2%), uterine (28.1%) and endometrial (19.5%) (https://www.cancer.gov/tcga). Since CDK9 phosphorylation of RNA polymerase II is required for transcription of Myc mRNA, we evaluate VIP152, a highly selective CDK9 inhibitor (Lücking et al 2021), to deliver antitumor responses in preclinical models of gynecologic malignancies. Methods: Gynecologic cell lines were treated with 9 dose levels of VIP152 with DMSO and cisplatin as controls. IC50 were calculated using CellTiter-Glo luminescent cell viability assay after 72 hours treatment. A preliminary analysis of 19 cell lines was undertaken to determine whether response to VIP152 is associated with baseline mutation, gene expression, or copy number variation data. Monotherapy efficacy of VIP152 was evaluated in a cisplatin sensitive A2780 in vivo xenograft mouse model. Results: Screening of gynecologic cell lines demonstrates a 3-log range of sensitivity with VIP152 IC50s ranging from 38-593nM. Simultaneous cisplatin screening identified sensitive and resistant cell lines in the same panel. Low VIP152 IC50s were observed in cell lines sensitive or resistant to cisplatin. Cell lines were assigned as sensitive and resistant based on the VIP152 IC50 values. Preliminary analysis suggests a gene signature could predict response to VIP152 in gynecologic malignancies. VIP152 was evaluated in an ovarian cancer A2780 in vivo xenograft model. Monotherapy treatment with 4 doses of VIP152 across 5 dose levels from 5- to 15-mg/kg weekly regimens provided increasing tumor growth inhibition compared with vehicle control. Conclusions: VIP152 demonstrates sensitivity in gynecologic cell lines independent of cisplatin sensitivity. An interim gene signature that is associated with VIP152 sensitivity was defined and we plan to optimize this signature with a larger cell line panel. Dose-dependent tumor growth inhibition in an in vivo xenograft model is demonstrated. VIP152 is currently being evaluated in the clinic (ClinicalTrials.gov Identifiers: NCT02635672 and NCT04978779). References: Gabay et al. 2014. Cold Spring Harb Perspect Med. 4(6):a014241. Lücking et al. 2021. J Med Chem. 64(15):11651-11674. Ramsay et al. 1984. PNAS. 81(24):7742-7746. Citation Format: Melanie M. Frigault, Hermes Garban, Joy M. Greer, Stuart Hwang, Raquel Izumi, Amy J. Johnson, Beatrix Stelte-Ludwig, Ahmed Hamdy. VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1859.

Abstract Background: Defining cancer and treatment-related factors which influence protection against COVID-19 following vaccination are important given the worse outcomes following infection in this group. Sophisticated and detailed studies which go beyond a single measure are required particularly with correlation to multiple disease and treatment factors. This study cohort is unique due to (a) very low prior COVID-19 infection at time of sampling (July-Nov 2021), (b) vaccines studied were BNT162b2 (Pf) given 3 weeks apart or ChAdOx1 (AZ) spaced 12 weeks (dose 1, 2) (c) most participants then received a third dose 2 months later (heterologous for AZ). Methods: SerOzNET (ACTRN12621001004853) enrols Australian blood and solid cancer patients prior to vaccination, with serial blood analyses and qualitative measures. We measured neutralizing antibodies (nAb) against SARS-CoV-2 wild type (wt) and variants of concern delta and omicron, quantitative S-protein IgG antibody level (Abbott), and T-cell correlates (interferon-g, tumour necrosis factor-a, interleukins 2/4/5/13) and epigenetic profiling at baseline and 3-4 weeks post dose 1, 2 +/- 3. Results: 379 participants were included, median age 58 years (IQR 47-66) and 60% female. 30% participants had hematological malignancies with the remainder solid organ cancers. 90% patients were on current systemic cancer treatment (most commonly chemotherapy in 41%, chemoimmunotherapy or immunotherapy in 20%). In 331 patients where treatment intent was recorded, 47% was palliative. Only one patient had known prior COVID-19 infection. Of the initial 94 participants who received Pf vaccination, median (IQR) neutralizing antibody titre 4 weeks following dose 2 was 80 (40-160) for SARS-CoV-2 wt and 40 (0-80) for delta variant. Conclusion: Neutralizing antibody titres in this Australian cancer population following Pf vaccination appear lower than those reported elsewhere such as CAPTURE study (Fendler et al, 2021), possibly related to shorter interdose interval. Preliminary data highlights low nAb titres as expected in haematology patients but also in some cases with treatment not traditionally associated with immunosuppression such as hormonal therapy. These results will be updated in February 2022 with third dose, AZ and omicron variant data. Citation Format: Eva Segelov, Amy Body, Vi Luong, Veronica Aedo Lopez, Luxi Lal, Hesham Abdulla, Stuart Turville, Zin Niang, Stephen Opat, Robert McCuaig, Katie Lineburg, Sudha Rao, Corey Smith, Raina MacIntyre, Elizabeth Ahern. Comprehensive humoral and cellular immune assessments to SARS-CoV-2 (wild type, delta and omicron) following two- and three-dose vaccination schedule in a large adult cancer population: SerOzNET study: placeholder abstract [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT259.

Abstract Leukemic blasts are immune cells gone awry. We thus hypothesized that dysregulation of inflammatory pathways can maintain a leukemic state. In contrast to traditional cancer immunotherapy, we exploited inflammatory signaling within AML blasts as cell-intrinsic, self-directed immunotherapy. Corroborating the hypothesis that AML cells depend on proper regulation of inflammatory networks, we identified an AML subgroup enriched for inflammatory pathways, associated with a monocytic lineage signature. To discover AML selective, immune-modulating vulnerabilities, we integrated data from the Cancer Dependency Map on 789 cancer cell lines with independent genome-wide screens, identifying Interferon regulatory factor 2 binding protein 2 (IRF2BP2). We validated AML cell dependency on IRF2BP2 with orthogonal genetic approaches in vitro and in vivo and studied acute IRF2BP2 degradation. Perturbation of IRF2BP2 resulted in cell death with hallmarks of apoptosis. To decipher how IRF2BP2 relates to inflammatory signaling, we studied IRF2BP2 localization on chromatin. We found genome-wide IRF2BP2 binding in promoter and in enhancer regions. Global gene expression studies following degradation of IRF2BP2 showed an increase in expression of the majority of IRF2BP2 bound genes, supporting a role for IRF2BP2 as a transcriptional repressor. Gene set enrichment analyses identified NF-κB-related immune response signatures as the most significantly altered leading us to hypothesize that IRF2BP2 represses NF-κB-mediated TNFα signaling that, when acutely perturbed, leads to leukemia cell death. Indeed, we confirmed an activation of NF-κB-signaling, an increase in nuclear RELA protein, and gain in RELA chromatin binding following degradation of IRF2BP2. Moreover, a mutant “super-repressor” allele of IκBα rescued the impaired cell growth upon IRF2BP2 perturbation, supporting cell death associated with IRF2BP2 loss being mediated through activation of NF-κB signaling. In addition, we identified IL-1ß as an enhancer of the inflammatory response repressed by IRF2BP2. Using patient-derived xenograft models, we demonstrated a significant reduction in leukemia burden and an increase in median survival in mice that had received patient-derived AML cells with IRF2BP2-targeting CRISPR guides compared to control guides. Importantly, loss of IRF2BP2 in normal bone marrow-derived hCD34+ cells had no effect on colony forming capacity. In summary, we demonstrate that IRF2BP2 represses IL-1ß/TNFα signaling via NF-κB, and IRF2BP2 perturbation results in hyperinflammation leading to AML cell death. These findings elucidate a hitherto unexplored AML dependency, reveal cell-intrinsic inflammatory signaling as a mechanism priming leukemic blasts for cell death, and motivate the exploration of alternative immune-mediated therapies in cancers that have yet to reap the benefits of the immunotherapy revolution. Citation Format: Jana M. Ellegast, Gabriela Alexe, Amanda Hamze, Shan Lin, Hannah J. Uckelmann, Philipp J. Rauch, Maxim Pimkin, Linda Ross, Neekesh V. Dharia, Amanda L. Robichaud, Amy Conway Saur, Delan Khalid, Mark Wunderlich, Lina Benajiba, Behnam Nabet, Nathanael S. Gray, Stuart H. Orkin, Kimberly Stegmaier. Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB076.

-Leonard Y. Andaya, Michel Jacq-Hergoualc'h, The Malay Peninsula; Crossroads of the maritime silk road (100 BC-1300 AD). [Translated by Victoria Hobson.] Leiden: Brill, 2002, xxxv + 607 pp. [Handbook of oriental studies, 13. -Greg Bankoff, Resil B. Mojares, The war against the Americans; Resistance and collaboration in Cebu 1899-1906. Quezon city: Ateneo de Manila University, 1999, 250 pp. -R.H. Barnes, Andrea Katalin Molnar, Grandchildren of the Ga'e ancestors; Social organization and cosmology among the Hoga Sara of Flores. Leiden: KITLV Press, 2000, xii + 306 pp. [Verhandeling 185.] -Peter Boomgaard, Emmanuel Vigneron, Le territoire et la santé; La transition sanitaire en Polynésie francaise. Paris: CNRS Éditions, 1999, 281 pp. [Espaces et milieux.] -Clara Brakel-Papenhuyzen, Raechelle Rubinstein, Beyond the realm of the senses; The Balinese ritual of kekawin composition. Leiden: KITLV Press, 2000, xv + 293 pp. [Verhandelingen 181.] -Ian Caldwell, O.W. Wolters, History, culture, and region in Southeast Asian perspectives. Ithaca, NY: Southeast Asia program, Cornell University/Singapore: Institute of Southeast Asian studies, 1999, 272 pp. [Studies on Southeast Asia 26.] -Peter van Diermen, Jonathan Rigg, More than the soil; Rural change in Southeast Asia. Harlow, Essex: Prentice Hall / Pearson education, 2001, xv + 184 pp. -Guy Drouot, Martin Stuart-Fox, Historical dictionary of Laos. Second edition. Lanham, Maryland: The Scarecrow Press, 2001, lxi + 527 pp. [Asian/Oceanian historical dictionaries series 35.] [First edition 1992.] -Doris Jedamski, Elsbeth Locher-Scholten, Women and the colonial state; Essays on gender and modernity in the Netherlands Indies 1900-1942. Amsterdam: Amsterdam University Press, 2000, 251 pp. -Carool Kersten, Robert Hampson, Cross-cultural encounters in Joseph Conrad's Malay fiction. Basingstoke: Palgrave, 2000, xi + 248 pp. -Victor T. King, C. Michael Hall ,Tourism in South and Southeast Asia; Issues and cases. Oxford: Butterworth-Heinemann, 2000, xiv + 293 pp., Stephen Page (eds) -John McCarthy, Bernard Sellato, Forest, resources and people in Bulungan; Elements for a history of settlement, trade and social dynamics in Borneo, 1880-2000. Jakarta: Center for international forestry research (CIFOR), 2001, ix + 183 pp. -Naomi M. McPherson, Michael French Smith, Village on the edge; Changing times in Papua New Guinea. Honolulu: University of Hawai'i Press, 2002, xviii + 214 pp. -Gert J. Oostindie, Peter van Wiechen, Vademecum van de Oost- en West-Indische Compagnie Historisch-geografisch overzicht van de Nederlandse aanwezigheid in Afrika, Amerika, Azië en West-Australië vanaf 1602 tot heden. Utrecht: Bestebreurtje, 2002, 381 pp. -Gert J. Oostindie, C.L. Temminck Groll, The Dutch overseas; Architectural Survey; Mutual heritage of four centuries in three continents. (in cooperation with W. van Alphen and with contributions from H.C.A. de Kat, H.C. van Nederveen Meerkerk and L.B. Wevers), Zwolle: Waanders/[Zeist]: Netherlands Department for Conservation, [2002]. 479 pp. -Gert J. Oostindie, M.H. Bartels ,Hollanders uit en thuis; Archeologie, geschiedenis en bouwhistorie gedurende de VOC-tijd in de Oost, de West en thuis; Cultuurhistorie van de Nederlandse expansie. Hilversum: Verloren, 2002, 190 pp. [SCHI-reeks 2.], E.H.P. Cordfunke, H. Sarfatij (eds) -Henk Schulte Nordholt, Tony Day, Fluid iron; State formation in Southeast Asia. Honolulu: University of Hawai'i Press, 2002, xii + 339 pp. -Nick Stanley, Nicholas Thomas ,Double vision; Art histories and colonial histories in the Pacific. Cambridge: Cambridge University Press, 1999, xii + 289 pp., Diane Losche, Jennifer Newell (eds) -Heather Sutherland, David Henley, Jealousy and justice; The indigenous roots of colonial rule in northern Sulawesi. Amsterdam: VU Uitgeverij, 2002, 106 pp. -Gerard Termorshuizen, Piet Hagen, Journalisten in Nederland; Een persgeschiedenis in portretten 1850-2000. Amsterdam: Arbeiderspers, 2002, 600 pp. -Amy E. Wassing, Bart de Prins, Voor keizer en koning; Leonard du Bus de Gisignies 1780-1849; Commissaris-Generaal van Nederlands-Indië. Amsterdam: Balans, 2002, 288 pp. -Robert Wessing, Michaela Appel, Hajatan in Pekayon; Feste bei Heirat und Beschneidung in einem westjavanischen Dorf. München: Verlag des Staatlichen Museums für Völkerkunde, 2001, 160 pp. [Münchner Beiträge zur Völkerkunde, Beiheft I.] -Nicholas J. White, Matthew Jones, Conflict and confrontation in South East Asia, 1961-1965; Britain, the United States, Indonesia and the creation of Malaysia. Cambridge: Cambridge University Press, 2002, xv + 325 pp. -Edwin Wieringa, Peter Riddell, Islam and the Malay-Indonesian world; Transmission and responses. London: Hurst, 2001, xvii + 349 pp. -Edwin Wieringa, Stuart Robson ,Javanese-English dictionary. (With the assistance of Yacinta Kurniasih), Singapore: Periplus, 2002, 821 pp., Singgih Wibisono (eds) -Henk Schulte Nordholt, Edward Aspinall ,Local power and politics in Indonesia; Decentralisation and democracy. Sin gapore: Institute of Southeast Asian studies, 2003, 296 pp. [Indonesia Assessment.], Greg Fealy (eds) -Henke Schulte Nordholt, Coen Holtzappel ,Riding a tiger; Dilemmas of integration and decentralization in Indonesia. Amsterdam: Rozenburg, 2002, 320 pp., Martin Sanders, Milan Titus (eds) -Henk Schulte Nordholt, Minako Sakai, Beyond Jakarta; Regional autonomy and local society in Indonesia. Adelaide: Crawford House, 2002, xvi + 354 pp. -Henk Schulte Nordholt, Damien Kingsbury ,Autonomy and disintegration in Indonesia. London; RoutledgeCurzon, 2003, xiv + 219 pp., Harry Aveling (eds)

This study aims to determine the effect of local arbuscular mycorrhizal fungi (AMF) on weed density, growth and yield of sweet corn in marginal soils. This study used a randomized block design with local AMF propagules which consisted of 4 levels: 0 g/planting hole or control (A0), 15 g/planting hole (A1), 30 g/planting hole (A2) and 45 g/planting hole (A3). The research parameters observed were: weed density, plant height, stem diameter, crop yield, and the percentage of AMF infection in the roots of corn plants. The results showed that the highest weed dominance value at the age of 14 DAP was Cyperus rotundus as 36.8% in treatment of AMF 45 g/planting hole (A3), age 56 DAP the highest weed dominance value was Hyptis capitata as 47.1% in the treatment of AMF 30 g/planting hole. The best plant height and stem diameter were found in the treatment of AMF 45 g/planting holes (A3) at 56 DAP, the average plant height reached 234.05 cm and the average stem diameter reached 3.72 cm. Increased production of corn plants that were given local AMF ranged from 2.70 to 3.10 tons ha-1 or an average increase in overall corn crop production of 2.86 tons ha-1. The average percentage of mycorrhiza fungi infections in the highest roots of corn plants in the treatment of AMF 45 g/planting hole (A3) as 94%. Key words: Arbuscular mycorrhiza fungi; vesicles; hypha; maize; ultisols

This study aimed to determine the response of the growth of sweet corn plants and weed density to the treatment of bio-fertilizer based on arbuscular mycorrhizal fungi and cow manure fertilizer. The study was conducted using a randomized complete block design (RCBD) in a factorial pattern. The first factor was arbuscular mycorrhiza fungi (AMF) consisting of four doses, namely without AMF (A0), AMF 5 g/planting hole (A1), AMF 10 g/planting hole (A2), AMF 15 g/ planting hole (A3). The second factor was cow manure fertilizer con-sisting of three doses, namely without cow manure fertilizer (B0), cow manure fertilizer 3 kg/plot (B1), cow manure fertilizer 6 kg/plot (B2). The treatment applied consisted of 12 combinations of treatments with 3 replications, so there were 36 experimental units. The observed variables were plant height, stem diameter, leaf area and weed density. The results showed that the average height of sweet corn was best at 42 DAP in the treatment of cow manure fertilizer 6 kg/plot (B2) as 111.6 cm. The average highest of stems diameter was at 14 DAP in the treatment of cow manure fertilizer 6 kg/plot (B2) as 0.40 cm. The average leaf area of sweet corn was at the age of 28 DAP was highest in the combination treatments cow manure fertilizer 6 kg/ plot (A0B2) and without AMF as 894.5. The weed species with the highest density found was I.cylindrica as 0.5-32.4%, C. kyllingia as 1.3-41.8%, C. rotundus as 1.3-30.3% and F.miliaceae as 1.2-12.7%.

This study aims to determine the performance yield component of sweet corn and weed density due to different kinds of fertilizer treatments. This study uses a randomized complete block design (RCBD) in factorial patterns with two factors. The first factor is biofertilizer-Arbuscular mycorrhiza fungi (biofertilizer-AMF) which consists of four levels, namely without biofertilizer-AMF (A0), biofertilizer-AMF 5 g/planting hole (A1), biofertilizer-AMF 10 g/planting hole (A2), biofertilizer-AMF 15 g/planting hole (A3). The second factor is cow manure fermented consisting of three levels, namely without cow manure (B0), cow manure 5 tons ha-1 (B1), cow manure 10 tons ha-1 (B2) with 3 replications so that there are 36 experimental units. The variables observed in this study were: cob length (cm), cob diameter (cm), number of seed rows, cob weight with husk (g), cob weight without husk (g) productivity of sweet corn plants (ton ha-1) and kinds of weeds and their absolute density. The results showed that the highest average corn crop productivity was obtained in the treatment without biofertilizer-AMF and cow manure fermented 10 tons ha-1 (A0B2) as 8.52 tons ha-1. If the combination of treatments contained biofertilizer-AMF and cow manure fermented, the highest average productivity of sweet corn was obtained in the treatment of biofertilizer-AMF 5 g/planting hole and cow manure fermented 10 tons ha-1 (A1B2) as 7.19 tons ha-1. The highest weed density from broadleaf is H.capitata (34.167%), from grasses is I.cylindrica (32.432%) and from sedges is Cyperus sp (30.21%).

This study aims to determine the effectiveness of arbuscular mycorrhiza fungi and cow manure to yield of sweet corn on Ultisol. This research was conducted using a randomized block design (RCBD) in a factorial pattern. The first factor is arbuscular mycorrhizal fungi (AMF) which consists of four levels, namely without AMF (A0), AMF 5 g/planting hole (A1), AMF 10 g/planting hole (A2), AMF 15 g/planting hole (A3). The second factor is cow manure fertilizer (CMF) consisting of three levels, namely without CMF (B0), CMF 5 tons ha-1 (B1), CMF 10 tons ha-1 (B2). The treatment applied consisted of 12 treatment combinations which were repeated in 3 replications, so that there were 36 experimental units. The observed variables were: weight of cob with cob, weight of cob without cob, cob length, ear diameter, number of rows of seeds and crop production (ton ha-1). The results showed that the highest average weight cob with husk was obtained in a combination treatment of AMF 10 g/planting hole and without CMF (A2B0) as 289.2 g. The highest average corn crop productivity was obtained in the combination of treatment without AMF and CMF 5 tons ha-1 (A0B1) as 8.52 tons ha-1.

Jak scharakteryzować termin "emancypacja poprzez edukację"? Emancypacja jest to proces, który prowadzi do równości społecznej, wolności politycznej i realnej możliwości jednostki na postęp. Egalitarna edukacja oznacza, że wiedza jest dostępna dla każdego - niezależnie od jego klasy społecznej, płci, rasy i narodowości. To nauczanie ludzi z uciskanych lub dyskryminowanych grup, by walczyć z niesprawiedliwością i nauczanie ich aby bronić swoich już osiągniętych praw. Idea emancypacji poprzez edukację rozumiana w taki sposób wyłoniła się w okresie Oświecenia, który obejmował czasy przed, w trakcie i tuż po rewolucji francuskiej. Wtedy ten pomysł ewoluował przez całą nowoczesną erę, która kończy się na początku II wojny światowej. W moim eseju "Emancypacja poprzez edukację: od Oświecenia po Pragmatyzm" studiuję emancypacyjne wątki obecne w filozoficznych teoriach takich myślicieli, jak Jean Jacques Rousseau, Jean Antoine Condorcet, Mary Wollstonecraft, Immanuel Kant, Friedrich Schiller, John Stuart Mill, Harriet Taylor Mill, Karl Marx, Fryderyk Engels, Antonio Gramsci i John Dewey. Podczas przeprowadzania moich badań odkryłam, że niektórzy z nowoczesnych myślicieli reprezentowali pozycję emancypacyjną tylko w części swoich pomysłów, podczas gdy w drugiej części ich myśli pozostały konserwatywne. Na przykład Rousseau - jeden z ojców emancypacyjnej pedagogiki - był przeciwny udziałowi kobiet w przestrzeni publicznej. Innym przykładem jest użycie siły piękna i radości, aby poddać "impulsywne" masy kontroli "racjonalnych" elit w wizji Schillera dotyczącej pedagogiki estetycznej. Analizuję te "zaniechania" za pomocą krytycznych dyskursów ja ta Carole Pateman czy Terry'ego Eagletona.

This panel was convened at 1:45 p.m., Friday, March 26, 2021, by the ASIL-Midwest Interest Group. Through a roundtable discussion, the panel explored the changes that the pandemic has had on the practice and teaching of international law. Professor Brian Farrell and Professor Stuart Ford, Co-Chairs of the Midwest Interest Group, co-moderated the panel discussion and introduced the panelists: Juliet Sorensen of the Northwestern Pritzker School of Law; Lawrence Schaner of Schaner Dispute Resolution LLC; Kanglin Yu of the University of Iowa College of Law; Dr. Robert Eno, Registrar of the African Court of Human and Peoples’ Rights; and Vera Korzun of the University of Akron School of Law.

The paper by Anderson-Whymark, Garrow and Sturt raises very important questions about how we understand Later Mesolithic Britain, Ireland and continental Europe. National research traditions have, at times, obscured our understanding of contacts and connections between areas in the Mesolithic. A focus on the distribution of a small range of artefacts has created a situation where Mesolithic cultures begin to resemble nation-states (Marchand 2014: 11). Our terminology reflects and reifies these distinctions. If we wish to understand how social geographies within Britain and Ireland change over time, it is unhelpful, to say the least, that they should have such inconsistent period terminology: the British Early Mesolithic is absent from Ireland; the British Later Mesolithicisthe Irish Early Mesolithic; and the Irish Later Mesolithic does not exist in Britain. The continental terminology is different again, and linguistic barriers remain a problem to regional-level synthesis. Anderson-Whymarket al.'s engagement with the loving detail of French lithic typology is hence to be welcomed.

Hugo Anderson-Whymark, Duncan Garrow and Fraser Sturt are to be congratulated on an important find and a robust evaluation of its significance. As they point out, it was Roger Jacobi who first introduced the notion that Britain had been culturally isolated from the continent following the flooding of the English Channel; this was on the basis of stylistic differences between the microlithic assemblages found in the two areas in the later Mesolithic. Equally, although Villeneuve-Saint-Germain communities were established in Normandy early in the fifth millennium BC, and Chassey/Michelsberg groups in the Pas-de-Calais perhaps six hundred years later, the material evidence of their cross-Channel relations with British and Irish hunter-gatherers is limited. On this basis, the view has developed that indigenous people in Britain would have been unaware of the developing Neolithic in France and Belgium. Consequently, they would have had no familiarity with domesticated plants and animals, polished stone tools, ceramics, large timber buildings and mortuary monuments until such innovations were brought to these islands by migrating agriculturalists at the end of the millennium. If Mesolithic people played any part at all in the Neolithic transition, it would only have been after the arrival of settlers on these shores.

Życie Dolley Payne Madison było naprawdę niezwykłe. Od skromnej dziewczyny ze wspólnoty kwakrów do najbardziej znanej kobiety w Stanach Zjednoczonych. Interesujący jest zwłaszcza okres z czasów waszyngtońskich. Dolley mieszkała w mieście federalnym łącznie 26 lat. Po raz pierwszy, gdy jej mąż, James Madison, przyjął pozycję sekretarza stanu w administracji Thomasa Jeffersona. W tamtym okresie Waszyngton nie przypominał wyglądem stolicy kraju. Było tam niewiele zabudowań, kilka pensjonatów i nieukończone budynki rządowe. Szybko okazało się jednak, że było to miejsce wymarzone dla Dolley. Brak ugruntowanej sceny towarzyskiej dawał jej szansę na stworzenie własnej. Pierwsza okazja pojawiła się, gdy owdowiały prezydent poprosił ją, aby pełniła funkcję gospodyni Domu Prezydenta podczas jednego z oficjalnych obiadów. Pani Madison tak zaimponowała Jeffersonowi, że wkrótce stała się oficjalną gospodynią Domu Prezydenta. Ta funkcja dawała jej wyjątkową pozycję w towarzystwie waszyngtońskim. Dolley była niezwykle miłą i ciepłą osobą, co sprawiało, iż wszyscy czuli się w jej towarzystwie komfortowo. Dzięki swojej pozycji pani Madison niejednokrotnie znajdowała się w centrum politycznych i dyplomatycznych batalii, jak chociażby w przypadku sprawy Anthony’ego i Elizabeth Merry. Ponadto miała okazję spotkać wybitne osobowości jej czasów, jak malarza G. Stuarta, przyrodnika i podróżnika A. von Humboldta czy podróżników M. Lewisa i W. Clarka. Dolley prowadziła również swój własny salon, który szybko stał się głównym miejscem spotkań towarzystwa waszyngtońskiego. Po zaprzysiężeniu Jamesa Madisona na czwartego prezydenta Stanów Zjednoczonych, Dolley przejęła rządy w Domu Prezydenta. Mogła w końcu wprowadzić własne zasady. Kontynuowała tradycję przyjęć w swoim salonie, ale dodała nowe elementy, jak choćby tzw. przyjęcia gołębie dla żon członków gabinetu. Swoją elegancją zarówno w zachowaniu, jak i w ubiorze nie miała sobie równych. Stała się waszyngtońską królową. Drugą kadencję prezydentury Madisona okryły cienie wojny 1812 r. Obraz Dolley Madison uciekającej z Domu Prezydenta przed atakującymi Brytyjczykami z portretem Washingtona pod pachą wyrył się w pamięci ówczesnych, jak i kolejnych pokoleń. Już za jej życia pojawiały głosy negujące prawdziwość tej historii. Dolley walczyła jednak z podobnymi pomówieniami odbierającymi jej główną rolę w tym wydarzeniu. Wojska brytyjskie dokonały ogromnych zniszczeń w mieście. Dolley niezwłocznie wróciła do wcześniejszego programu przyjęć i spotkań, aby wspomóc administrację męża i poprawić wizerunek rządu. Pani Madison zajęła się również pracą charytatywną na rzecz lokalnej społeczności, pomagając powołać pierwszy w historii miasta sierociniec. Po skończonej prezydenturze państwo Madison powrócili do Montpelier. Po śmierci męża Dolley powróciła do miasta federalnego. Pełniła wtedy zupełnie inną rolę. Stała się waszyngtońską ikoną. Nie było wydarzenia, na które nie zostałaby zaproszona w charakterze gościa honorowego. Brała udział w inauguracji prezydenta, balach, oficjalnych kolacjach. Często przysłuchiwała się debatom w Kongresie. Jako pierwsza przesłała prywatną wiadomość telegraficzną. Była powszechnie poważana i szanowana. Dolley Madison zmarła 12 lipca 1849 r. w mieście, którego charakter pomogła ukształtować, w domu mieszczącym się tuż obok Domu Prezydenta, z którym była przez tyle lat związana.

Pediatric AML is a heterogeneous disease in which treatment resistance remains an unsolved problem that is responsible for most deaths (Yeung and Radich 2017). Recently we have come to learn that resistance may be driven by mechanisms that extend beyond somatic mutations and DNA methylation changes (Ghasemi et al. 2020; van Galen et al. 2019; Bell et al. 2019). Transcriptional changes within specific primitive and committed cell types in AML tumours, which may be accompanied by alterations in chromatin structure and topology, can also contribute to disease progression (Ghasemi et al. 2020). To study such changes at the single-cell level, we analyzed single-cell RNA-seq (scRNA-seq) and matched scATAC-seq data from primary, remission and/or relapse samples obtained from three pediatric AML patients enrolled in the AAML1031 clinical trial (Alpenc et al. 2016) (Figure 1). Using the 10X Genomics single-cell platforms, we profiled a total of 39,738 cells using scRNA-seq (~4,826 cells per sample, 1,571 genes per cell), and 46,580 cells and 197,128 peaks using scATAC-seq (~6,718 cells per sample, 5,628 unique reads per cell). We then integrated these data types to determine the extent to which these two modalities corroborated and/or complemented each other in analyses of these longitudinally-obtained samples. Cell subpopulations detected in scRNA-seq through Leiden clustering on a k-nearest neighbor graph were generally consistent with recent observations of malignant and normal cell types detected in the bone marrow and peripheral blood compartments (van Galen et al. 2019; Hay et al. 2018). Malignant-like subpopulations at primary and relapse stages exhibited similar levels of cell type diversity along the myeloid lineage. These included hematopoietic stem-like cells, progenitors, granulocyte-monocyte progenitors, monocytes and dendritic cell-like subpopulations. Remission samples appeared to contain normal blood cell types including natural killers (NK), B and T cells, platelets and erythrocytes, consistent with the clearance of blasts. However, we also observed putative malignant-like conventional dendritic cell subpopulations at remission (50% and 16% in the respective samples), noting that these cells displayed increased expression of genes involved in antigen presentation and lysosomal protein processing. To integrate scATAC-seq with scRNA-seq data we performed clustering of transformed and reduced scATAC-seq data through iterative latent semantic indexing (Granja et al. 2020), and aligned cells in scATAC-seq to cells from scRNA-seq data using canonical correlation analysis (Stuart et al. 2019). We observed similar patterns of T cell expansion, presence of monocyte-like populations and NK cells at remission in the scATAC-seq data. However, scRNA-seq subpopulations dominated by malignant-like cells showed variability in mapping to distinctive chromatin states, with a few notable exceptions (Figures 2 and 3). One such exception is a subpopulation in scRNA-seq, found mostly at relapse, marked by high expression of genes involved in proliferation and growth factor-mediated cellular processes such as YBX3 (binds to GM-CSF promoter), CYTL1, and EGFL7 (regulator of vasculogenesis) (Figures 3 and 4). Cells within this subpopulation mapped to two scATAC-seq clusters whose significantly more highly accessible regions were enriched for functional processes such as blood vessel remodeling and neutrophil/granulocyte activation (Figure 4). These observations are consistent with recent evidence that AML tumour cells can activate the immune system to acquire resistance (Melgar et al. 2020). The scRNA-seq subpopulation, however, did not display high expression of myeloid/granulocyte factors such as CD15, ELANE, and MPO (Figure 4), perhaps consistent with the notion that such transcriptional programs may be primed but not yet activated within these malignant cells. We thus evaluated the potential of scATAC-seq to complement scRNA-seq in understanding transcriptional changes within cell types in AML tumours. We observed that normal cell types and specific malignant cell states could occupy distinctive chromatin states. Through integrative analyses, we conclude that scATAC-seq results can add additional information to complement scRNA-seq data, including identifying nascent transcriptional programs that may be poised for activation within malignant cells. Disclosures No relevant conflicts of interest to declare.

Abstract BACKGROUND: Recurrent isocitrate dehydrogenase (IDH) 1 mutations are observed in 6-10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120), a potent, selective, oral, small-molecule inhibitor of the mutant IDH1 (mIDH1) protein, is a promising therapeutic candidate for the treatment of patients with mIDH1 AML. Through inhibition of mIDH1, ivosidenib suppresses the abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to clinical responses via differentiation of malignant cells. AIM: To report safety and efficacy data from the first-in-human phase 1 study of ivosidenib in patients with mIDH1 advanced hematologic malignancies including relapsed/refractory (R/R) AML (NCT02074839). This is the first report of data from the 4 expansion cohorts, with a total of 258 patients treated on study. METHODS: The ongoing phase 1 study assesses the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and clinical activity of ivosidenib in mIDH1 hematologic malignancies. Enrollment was completed on May 8, 2017. During dose escalation, patients received ivosidenib as a single agent orally once daily (QD) or twice daily (BID) in 28-day cycles. The MTD was not reached and 500 mg QD was selected as the recommended dose to be tested in 4 expansion cohorts: R/R AML (Arms 1 and 4, where Arm 1 patients are those with relapse after transplantation, second or later relapse, resistance to initial induction or reinduction treatment, or relapse within 1 year of initial treatment, and Arm 4 patients have R/R AML but are not eligible for Arm 1); untreated AML (Arm 2); and other advanced hematologic malignancies including myelodysplastic syndrome (MDS) (Arm 3). Updated safety data will be presented for all patients. Efficacy outcomes will be presented for all R/R AML patients treated at 500 mg QD across the dose escalation and expansion cohorts who received their first dose of ivosidenib at least 6 months prior to the analysis cut-off date of May 12, 2017, as well as for the poorest prognosis Arm 1 subset. Efficacy data for all treated patients from the other expansion cohorts (untreated AML and other advanced hematologic malignancies including MDS) will also be presented. RESULTS: In all, 258 patients (78 in dose escalation, 180 in expansion) were treated with ivosidenib. As of May 12, 2017, 62 of 258 (24%) patients were continuing on treatment. The median duration of exposure to ivosidenib was 3.5 months (range 0.1-33.5). Twenty-two (8.5%) patients discontinued treatment to proceed to allogeneic stem cell transplantation. Treatment was well tolerated; the most common adverse events (AEs) (n=258) of any grade irrespective of causality occurring in ≥20% of patients were diarrhea (33%), leukocytosis (30%), nausea (30%), fatigue (29%), febrile neutropenia (25%), dyspnea (24%), anemia (23%), QT prolongation (23%), peripheral edema (22%), pyrexia (21%), and decreased appetite (20%). The majority of these AEs were grades 1-2 and reported as unrelated to treatment. Differentiation syndrome (DS) was observed in 29 of 258 (11.2%) patients, including grade ≥3 DS in 14 (5.4%); study drug was held owing to DS in 11 patients (4.3%), and no instances of DS led to permanent treatment discontinuation or death. The primary efficacy endpoint for R/R AML is the CR+CRh rate, i.e., the rate of complete remission (CR according to modified IWG 2003 criteria plus CR with partial hematologic recovery, defined as CR except absolute neutrophil count >0.5 × 109/L [500/µL] and platelet count >50 × 109/L [50,000/µL]). Among 125 Arm 1 R/R AML patients receiving ivosidenib 500 mg QD across dose escalation and expansion who received their first dose at least 6 months prior to the analysis cutoff date, the CR+CRh rate was 30.4% (95% CI 22.5%, 39.3%), including CR in 27 (21.6%) and CRh in 11 (8.8%) patients. Median duration of CR+CRh was 8.2 months (95% CI 5.5, 12.0), and duration of CR was 9.3 months (95% CI 5.6, 18.3). The overall response rate (CR+CRi/CRp+PR+MLFS) was 41.6% (95% CI 32.9%, 50.8%) (52/125 patients). CONCLUSION: Ivosidenib monotherapy is well tolerated in patients with mIDH1 AML and other advanced hematologic malignancies. In a high-risk, molecularly defined R/R AML patient population with unmet medical need, ivosidenib induced durable remissions and improved patient outcomes. These findings support the role of ivosidenib as an effective, oral, targeted treatment for patients with mIDH1 AML. Disclosures DiNardo: Celgene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Daiichi-Sankyo: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. De Botton: Pfizer: Honoraria; Novartis: Honoraria; Celgene: Honoraria; Servier: Honoraria; Agios: Honoraria, Research Funding. Stein: GSK: Other: Advisory Board, Research Funding; Constellation Pharma: Research Funding; Seattle Genetics: Research Funding; Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Celgene Corporation: Consultancy, Other: Travel expenses, Research Funding; Pfizer: Consultancy, Other: Travel expenses; Novartis: Consultancy, Research Funding. Roboz: AbbVie, Agios, Amgen, Amphivena, Array Biopharma Inc., Astex, AstraZeneca, Celator, Celgene, Clovis Oncology, CTI BioPharma, Genoptix, Immune Pharmaceuticals, Janssen Pharmaceuticals, Juno, MedImmune, MEI Pharma, Novartis, Onconova, Pfizer, Roche Pharmace: Consultancy; Cellectis: Research Funding. Mims: Novartis: Honoraria. Pollyea: Takeda, Ariad, Alexion, Celgene, Pfizer, Pharmacyclics, Gilead, Jazz, Servier, Curis: Membership on an entity's Board of Directors or advisory committees; Agios, Pfizer: Research Funding. Altman: Syros: Consultancy; NCCN: Other: Educational speaker; BMS: Consultancy; Celgene: Consultancy; Astellas: Consultancy; Ceplene: Consultancy; Janssen Pharmaceuticals: Consultancy; Novartis: Consultancy; ASH: Other: Educational speaker. Collins: Celgene Corporation: Research Funding; Agios: Research Funding; Arog: Research Funding; BMS: Research Funding. Mannis: Curis: Honoraria; Juno: Research Funding; Agios: Research Funding; Amgen: Honoraria. Uy: GlycoMimetics: Consultancy; Novartis: Consultancy, Other: Travel Suppport; Boehringer Ingelheim: Consultancy. Fathi: Juno: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding; Agios: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Medimmune: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Stein: Amgen: Consultancy, Speakers Bureau; Stemline: Consultancy. Erba: Celgene: Consultancy, Other: Chair, Scientific Steering Committee , Speakers Bureau; Incyte: all research support paid to University of Alabama, Consultancy, Speakers Bureau; Jazz: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Amgen: Consultancy, Other: all research support paid to University of Alabama, Research Funding; Daiichi Sankyo: Consultancy, Other: all research support paid to University of Alabama, Research Funding; ImmunoGen: Consultancy, Other: all research support paid to University of Alabama, Research Funding; MacroGen: Consultancy; Ono: Consultancy; Pfizer: Consultancy; Seattle Genetics: Consultancy, Other: all research support paid to University of Alabama, Research Funding; Sunesis: Consultancy; Millennium/Takeda: Consultancy, Other: all research support paid to University of Alabama, Research Funding; Agios: Other: all research support paid to University of Alabama, Research Funding; Juno: Other: all research support paid to University of Alabama, Research Funding; Astellas: Other: all research support paid to University of Alabama, Research Funding; Celator: Other: all research support paid to University of Alabama, Research Funding; Janssen: Other: all research support paid to University of Alabama, Research Funding; Glycomimetics: Other: Chair, Data and Safety Monitoring Committee. Traer: ImmunoGen: Consultancy; Tolero: Consultancy; Notable Labs: Equity Ownership. Stuart: Pharmacyclics LLC, an AbbVie Company: Research Funding; Amgen: Consultancy, Honoraria; Agios: Research Funding; Celator/Jazz: Research Funding; Sunesis: Consultancy, Honoraria, Other: Travel Support, Research Funding; Bayer: Research Funding; Novartis: Research Funding; Incyte: Research Funding; ONO: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Research Funding; MedImmune: Research Funding; Cantex: Research Funding; Astellas: Research Funding. Arellano: Cephalon Oncology: Research Funding. Sekeres: Celgene: Membership on an entity's Board of Directors or advisory committees. Yen: Agios: Employment, Equity Ownership. Kapsalis: Agios: Employment, Equity Ownership. Liu: Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Goldwasser: Agios: Employment, Equity Ownership. Agresta: Agios Pharmaceuticals, Inc.: Employment, Equity Ownership. Attar: Agios: Employment, Equity Ownership. Stone: Novartis: Consultancy; Celgene: Consultancy; Amgen: Consultancy; Abbvie: Consultancy; Fuji Film: Consultancy; Jazz: Consultancy; Astellas: Consultancy; Pfizer: Consultancy; Arog: Consultancy; Ono: Consultancy; Agios: Consultancy; Sumitomo: Consultancy. Kantarjian: ARIAD: Research Funding; Bristol-Meyers Squibb: Research Funding; Delta-Fly Pharma: Research Funding; Amgen: Research Funding; Pfizer: Research Funding; Novartis: Research Funding.

Abstract Background: CPX-351 (United States: Vyxeos ®; Europe: Vyxeos ® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes in adults and pediatric patients aged ≥1 year in the United States and in adults in the European Union. In a phase 3 study in adults aged 60 to 75 years with newly diagnosed high-risk/secondary AML who were eligible for intensive chemotherapy (IC), after 5 years of follow-up CPX-351 significantly improved median overall survival versus conventional 7+3 cytarabine/daunorubicin, with a comparable safety profile. Venetoclax (VEN; BCL-2 inhibitor) + low-dose cytarabine has demonstrated efficacy in unfit patients with AML, and preclinical data support a rationale for combining CPX-351 + VEN. This study evaluates the safety and efficacy of lower-dose CPX-351 + VEN in adults with newly diagnosed AML who are considered unfit to receive IC. Methods: This is an ongoing, open-label, multicenter, phase 1b study (NCT04038437) to determine the recommended phase 2 dose (RP2D) and evaluate the safety and efficacy of lower-dose CPX-351 + VEN in adults with newly diagnosed AML who are considered unfit to receive IC. The dose-exploration phase (3+3 design; n ≤24) evaluated multiple dose levels of CPX-351 on Days 1 and 3 + VEN 400 mg on Days 2 to 21 of each cycle to determine the RP2D. Patients who achieve at least partial remission after 1 or 2 cycles may receive up to 4 similar cycles of CPX-351 + VEN. During the expansion phase, 20 additional patients will receive CPX-351 + VEN at the RP2D. Patients are assessed for response by morphology and measurable residual disease (MRD) testing and are monitored for safety and survival. Results: This preliminary analysis includes data from 14 enrolled patients. Patients were considered unfit for IC based on age ≥75 years (n = 7 [50%]) or health (aged 18 to 74 years with an EGOC performance status of 2 or 3 [n = 3 (21%)] and/or comorbidities [n = 5 (36%]). Overall, 50% of the patients had poor-risk cytogenetics, 64% were male, 71% had a diagnosis of de novo AML, and 29% had mutated TP53 (Table 1). Four patients received dose level 1 (CPX-351 20 units/m 2 [daunorubicin 8.8 mg/m 2 + cytarabine 20 mg/m 2] + VEN), with no dose-limiting toxicities (DLTs) observed in the 3 evaluable patients. Seven patients were subsequently enrolled in dose level 2 (CPX-351 40 units/m 2 [daunorubicin 17.6 mg/m 2 + cytarabine 40 mg/m 2] + VEN), with 6 patients evaluable for DLTs. At dose level 2, 1 patient experienced 2 DLTs (grade 3 tumor lysis syndrome and liver injury); review of the overall safety profile led to a protocol amendment that permitted de-escalation to dose level 1b (CPX-351 30 units/m 2 [daunorubicin 13.2 mg/m 2 + cytarabine 30 mg/m 2] + VEN). Three patients received dose level 1b with no DLTs and a safety profile comparable to dose level 1. Together, these data established dose level 1b as the RP2D. The most common nonhematologic treatment-emergent adverse events (TEAEs) were gastrointestinal events and peripheral edema (Table 2). The majority (86%) of patients experienced a grade ≥3 TEAE, primarily myelosuppression; the only nonhematologic grade ≥3 TEAE in >10% of patients was tumor lysis syndrome (14%). No patient experienced early mortality by Day 30; the mortality rate at Day 60 was 7% due to 1 death in the dose level 1 cohort (myocardial infarction considered unrelated to treatment). Among the 12 patients evaluable for efficacy across dose levels, 8 (67%) achieved a best response of complete remission (CR): 3/4 (75%) in dose level 1, 3/5 (60%) in dose level 2, and 2/3 (67%) in dose level 1b. All patients who achieved a best response of CR entered into either CR or CR with incomplete neutrophil or platelet recovery after the first treatment cycle. Confirmation of MRD status is currently ongoing. Conclusions: Preliminary results from this ongoing phase 1b study established a RP2D of CPX-351 30 units/m 2 on Days 1 and 3 + VEN 400 mg on Days 2 to 21 in adults with newly diagnosed AML who were considered unfit to receive IC. The combination of lower-dose CPX-351 + VEN was generally well tolerated and demonstrated promising initial efficacy, with achievement of CR in the majority of patients. This study is ongoing and enrolling 20 additional patients to further evaluate the RP2D. Figure 1 Figure 1. Disclosures Uy: Novartis: Consultancy; GlaxoSmithKline: Consultancy; Agios: Consultancy; AbbVie: Consultancy; Macrogenics: Research Funding; Astellas: Honoraria, Speakers Bureau; Genentech: Consultancy; Jazz: Consultancy. Pullarkat: AbbVie, Amgen, Genentech, Jazz Pharmaceuticals, Novartis, Pfizer, and Servier: Membership on an entity's Board of Directors or advisory committees; Amgen, Dova, and Novartis: Consultancy, Honoraria. Baratam: Celgene/Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Stuart: Sunesis Pharmaceuticals: Consultancy; Sunesis Pharmaceuticals: Honoraria; Sunesis Pharmaceuticals: Other: Travel Support; Agios, Astellas Pharma, Bayer AG, Incyte, Jazz Pharmaceuticals, Ono Pharmaceuticals, and Sunesis Pharmaceuticals: Research Funding. Faderl: Jazz Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Chandrasekaran: Jazz Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Wang: Jazz Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Chakravarthy: Jazz Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Cheung: Jazz Pharmaceuticals: Current Employment, Current equity holder in publicly-traded company. Lin: AbbVie, Aptevo Therapeutics, Astellas Pharma, Bio-Path Holdings, Celgene, Celyad, Genentech-Roche, Gilead Sciences, Incyte, Jazz Pharmaceuticals, Novartis, Ono Pharmaceutical, Pfizer, Prescient Therapeutics, Seattle Genetics, Tolero, Trovagene: Research Funding. OffLabel Disclosure: combination of CPX-351 [Vyxeos] and venetoclax in adults with previously untreated AML

Abstract Background: Acute myeloid leukemia (AML) is driven by aberrant leukemic stem cells (LSCs) that initiate and sustain malignancy. To circumvent resistance to therapy, combination therapies with additive mechanisms of action are needed. CD70, a tumor necrosis factor receptor ligand, and its receptor CD27 are expressed on LSCs and AML blasts, but not on hematopoietic stem cells. Cusatuzumab, a high-affinity humanized monoclonal anti-CD70 antibody, kills CD70-expressing cells by Fc domain-mediated effector functions and is a potent inhibitor of CD70-CD27 signaling. Here we report initial results of a study of cusatuzumab in combination with the current standard of care therapy, venetoclax plus azacitidine (CVA), in patients with untreated AML (de novo or secondary) ineligible for intensive chemotherapy due to age ≥75 years or medical comorbidities. Methods: The primary objective of this open label, multicenter, phase 1b study was to assess safety and tolerability of CVA. Key secondary objectives included response rate per ELN 2017 criteria and time to response. Patients received cusatuzumab 10 or 20 mg/kg IV on Day 3 and Day 17, a 3-day ramp-up of venetoclax (100, 200, and 400 mg PO) followed by 400 mg daily dosing, and azacitidine 75 mg/m 2 SC or IV on Days 1-7 of each 28-day cycle. Results: Based on data through Jul 9, 2021, 44 patients enrolled with median age 75 years (range 32-89), 36.4% had secondary AML, 40.9% had an ECOG performance status of 2, and ELN risk was favorable, intermediate and adverse in 18.2%, 20.5% and 61.4%, respectively. All patients received 20 mg/kg cusatuzumab except for 3 patients who received a starting dose of 10 mg/kg with the option to escalate to 20 mg/kg. Of these 3 patients, 1 escalated to 20 mg/kg. At a median follow-up of 29.1 weeks, the median number of treatment cycles was 4.0 (range 1.0-11.0). Grade 3 or above TEAEs were reported in 97.7% of patients; the most common (reported in ≥10%) were neutropenia (68.2%), thrombocytopenia (65.9%), febrile neutropenia (36.4%), anemia (34.1%), leukopenia (29.5%), sepsis (27.3%), and lymphopenia (15.9%). Treatment-emergent serious adverse events (SAEs) were reported in 75% of patients; the most common (reported in at least ≥5%) were febrile neutropenia (27.3%), sepsis (22.7%), COVID-19 (6.8%), and thrombocytopenia (6.8%). Treatment-emergent SAEs of grade ≥3 were reported in 72.7% of the patients. Infusion-related reactions (IRRs) were reported for 11.4% of patients with 2.3% at grade ≥3. Six (13.6%) patients discontinued treatment due to AEs, and 5 (11.4%) TEAEs resulted in death. The mortality rate within 30 days from start of treatment was 4.5%. Table 1 summarizes best response to study treatment. In the intent-to-treat analysis set (n=44) complete remission (CR) rate was 45.5%, while CR + CR with partial hematologic recovery (CRh) + CR with incomplete hematologic recovery (CRi) was 77.3%; MLFS was observed in 11.4% of patients. Of 34 responders (defined as CR, CRi or CRh), 47% were MRD negative by flow cytometry at or after achievement of response. Median time to first response for patients who achieved CR, CRh or CRi was 4.21 (3.0-25.0) weeks. Best response rates in the post-hoc response evaluable analysis set (n=42) that excluded two patients who died before the first disease evaluation were: CR in 47.6%, CR + CRh + CRi in 81.0% and MLFS in 11.9% of patients (Table 1). The majority (97.1%) of responders experienced at least one cycle delay in administration of CVA post response. Conclusions: Cusatuzumab administered in combination with venetoclax and azacitidine to elderly patients with untreated AML was generally well tolerated and demonstrated a safety profile consistent with that previously reported with venetoclax-azacitidine, with the addition of generally manageable IRRs. Response rates support an additive effect of cusatuzumab to the standard of care with potential for improved clinical outcomes. However, further clinical trials are needed for validation of these initial results. HK and GB contributed equally to this publication. Figure 1 Figure 1. Disclosures Roboz: AstraZeneca: Consultancy; Janssen: Research Funding; Bristol Myers Squibb: Consultancy; Jasper Therapeutics: Consultancy; Agios: Consultancy; Novartis: Consultancy; Amgen: Consultancy; Blueprint Medicines: Consultancy; Janssen: Consultancy; Helsinn: Consultancy; Daiichi Sankyo: Consultancy; Glaxo SmithKline: Consultancy; Celgene: Consultancy; Jazz: Consultancy; MEI Pharma - IDMC Chair: Consultancy; Mesoblast: Consultancy; Actinium: Consultancy; AbbVie: Consultancy; Astex: Consultancy; Bayer: Consultancy; Astellas: Consultancy; Roche/Genentech: Consultancy; Pfizer: Consultancy; Otsuka: Consultancy. Aribi: Seagen: Consultancy. Brandwein: Astellas: Honoraria; Jazz: Honoraria; Amgen: Honoraria; Taiho: Honoraria; BMS/Celgene: Honoraria; Pfizer: Honoraria; Abbvie: Honoraria; University of Alberta: Current Employment. Döhner: Astellas: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Berlin-Chemie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Agios: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; GEMoaB: Consultancy, Honoraria; Helsinn: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Jazz: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Oxford Biomedicals: Consultancy, Honoraria; Pfizer: Research Funding; Roche: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Astex: Consultancy, Honoraria; Ulm University Hospital: Current Employment. Fiedler: Jazz Pharmaceuticals: Consultancy, Other: support for meeting attendance; Abbvie: Consultancy, Honoraria; Morphosys: Consultancy; Celgene: Consultancy; Pfizer: Consultancy, Research Funding; Novartis: Consultancy; ARIAD/Incyte: Consultancy; Amgen: Consultancy, Other: support for meeting attendance, Patents & Royalties, Research Funding; Servier: Consultancy, Other: support for meeting attendance; Daiichi Sankyo: Consultancy, Other: support for meeting attendance; Stemline: Consultancy. Gandini: argenx: Current Employment, Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months. Geddes: University of Calgary: Current Employment; Taiho: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy; Paladin: Consultancy; Janssen: Research Funding; Geron: Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding. Hou: University of Pittsburgh Medical Center Hillman Cancer Centers: Current Employment; AbbVie: Honoraria; AstraZeneca: Honoraria; Karyopharm: Honoraria; Chinese American Hematology Oncology Network: Membership on an entity's Board of Directors or advisory committees. Howes: Janssen R&D, part of Johnson & Johnson: Current Employment; Johnson & Johnson: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Hultberg: argenx: Current Employment, Patents & Royalties. Huselton: University of Rochester: Current Employment. Jacobs: Argenx BV: Current Employment, Current equity holder in publicly-traded company; University of Antwerp: Ended employment in the past 24 months. Kane: Janssen R&D, part of Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Lech-Marańda: Takeda: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding. Louwers: argenx: Current Employment, Patents & Royalties: Patents (no royalties). Nottage: Janssen R&D, part of Johnson & Johnson: Current Employment; Johnson & Johnson: Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Platzbecker: Novartis: Honoraria; AbbVie: Honoraria; Janssen: Honoraria; Celgene/BMS: Honoraria; Geron: Honoraria; Takeda: Honoraria. Rampal: Pharmaessentia: Consultancy; BMS/Celgene: Consultancy; Abbvie: Consultancy; Sierra Oncology: Consultancy; Incyte: Consultancy, Research Funding; Blueprint: Consultancy; Disc Medicine: Consultancy; Jazz Pharmaceuticals: Consultancy; Constellation: Research Funding; Kartos: Consultancy; Stemline: Consultancy, Research Funding; CTI: Consultancy; Novartis: Consultancy; Memorial Sloan Kettering: Current Employment. Salman: Janssen: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Shah: Janssen R&D, part of Johnson & Johnson: Current Employment. Stuart: Clinical Drug Development Consultants LLC: Current Employment; Argenx: Consultancy; Cleave Therapeutics: Consultancy; Triphase Accelerator Corp: Consultancy; IgM Biosciences: Consultancy; Revolution Medicines: Consultancy; Jiya Corp: Consultancy; Geron Corp: Current holder of individual stocks in a privately-held company. Subklewe: Janssen: Consultancy; Pfizer: Consultancy, Speakers Bureau; Takeda: Speakers Bureau; Klinikum der Universität München: Current Employment; MorphoSys: Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Roche: Research Funding; Seattle Genetics: Consultancy, Research Funding; Miltenyi: Research Funding; Gilead: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Research Funding, Speakers Bureau. Sumbul: argenx: Current Employment. Wang: Takeda: Consultancy, Honoraria, Other: Advisory board; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Stemline Therapeutics: Consultancy, Honoraria, Other: Advisory board, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite Pharmaceuticals: Consultancy, Honoraria, Other: Advisory Board; GlaxoSmithKline: Consultancy, Honoraria, Other: Advisory Board; Genentech: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees; DAVA Oncology: Consultancy, Speakers Bureau; Kura Oncology: Consultancy, Honoraria, Other: Advisory board, steering committee, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: Advisory Board; Mana Therapeutics: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Other: Advisory Board, Speakers Bureau; Rafael Pharmaceuticals: Other: Data safety monitoring committee; Gilead: Consultancy, Honoraria, Other: Advisory board; Daiichi Sankyo: Consultancy, Honoraria, Other: Advisory board; PTC Therapeutics: Consultancy, Honoraria, Other: Advisory board; Genentech: Consultancy; MacroGenics: Consultancy. Wierzbowska: Jazz: Research Funding; Pfizer: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria. Yao: Statagize LLC: Current Employment; Puma Biotechnology, Inc.: Ended employment in the past 24 months; Argenx: Consultancy. Yee: Astex: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Research Funding; TaiHo: Membership on an entity's Board of Directors or advisory committees; Otsuka: Membership on an entity's Board of Directors or advisory committees; Onconova: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees; Tolero: Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Paladin: Membership on an entity's Board of Directors or advisory committees; MedImmune: Research Funding; AbbVie: Honoraria; Bristol-Myers Squibb/Celgene: Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Forma Therapeutics: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Geron: Research Funding; Genentech: Research Funding; F. Hoffmann La Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Research Funding. Kantarjian: Immunogen: Research Funding; Astra Zeneca: Honoraria; KAHR Medical Ltd: Honoraria; Astellas Health: Honoraria; Pfizer: Honoraria, Research Funding; NOVA Research: Honoraria; Ascentage: Research Funding; Precision Biosciences: Honoraria; Novartis: Honoraria, Research Funding; Aptitude Health: Honoraria; Ipsen Pharmaceuticals: Honoraria; Jazz: Research Funding; Daiichi-Sankyo: Research Funding; BMS: Research Funding; Amgen: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Taiho Pharmaceutical Canada: Honoraria. Borthakur: Protagonist: Consultancy; Ryvu: Research Funding; Astex: Research Funding; GSK: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; University of Texas MD Anderson Cancer Center: Current Employment; ArgenX: Membership on an entity's Board of Directors or advisory committees.

Kelly, Stéphane. Les fins du Canada: selon Macdonald, Laurier, Mackenzie King et Trudeau. Par François Charbonneau 900Cross, William, ed. Political Parties, Representation, and Electoral Democracy in Canada. By Nelson Wiseman 901Boisvert, Yves, Jacques Hamel et Marc Molgat, sous la direction de. Vivre la citoyenneté. Identité, appartenance et participation. Par Christian Nadeau 903Doern, G. Bruce, Arslan Dorman and Robert W. Morrison, eds. Canadian Nuclear Energy Policy: Changing Ideas, Institutions, and Interests. By Genevieve Fuji Johnson 906Seymour, Michel. Le pari de la démesure. L'intransigeance canadienne face au Québec. Par François Rocher 908Doran, Charles F. Why Canadian Unity Matters and Why Americans Care: Democratic Pluralism at Risk. By Garth Stevenson 910Bakvis, Herman and Grace Skogstad, eds. Canadian Federalism: Performance, Effectiveness, and Legitimacy. By Willem Maas 912Poitras, Guy. Inventing North America: Canada, Mexico and the United States. By Maureen Appel Molot 914Cuccioletta, Donald, Jean-François Côté et Frédéric Lesemann, sous la direction de. Le grand récit des Amériques. Polyphonie des identités culturelles dans le contexte de la mondialisation. Par Jean Rousseau 915Pue, W. Wesley, ed. Pepper in our Eyes: The APEC Affair. By Sharon A. Manna 918Delannoi, Gil et Pierre-André Taguieff, sous la direction de. Nationalismes en perspective. Par Frédéric Boily 920Stevenson, Garth. Community Besieged: The Anglophone Minority and the Politics of Quebec. By Stephen Brooks 923Mény, Yves and Yves Surel, eds. Democracies and the Populist Challenge; and Taggart, Paul. Populism. By Andrej Zaslove 924Gainsborough, Juliet F. Fenced Off: The Suburbanization of American Politics. By Andrew Sancton 927Sineau, Mariette. Profession : femme politique. Sexe et pouvoir sous la Cinquième république. Par Chantal Maillé 928Nissen, Bruce, ed. Which Direction for Organized Labor? Essays on Organizing, Outreach, and Internal Transformations. By Greg Albo 931Dashwood, Hevina S. Zimbabwe: The Political Economy of Transformation. By Sara Rich Dorman 933Bonin, Pierre-Yves, sous la direction de. Mondialisation : perspectives philosophiques. Par Hélène Pellerin 935Diamond, Larry and Ramon H. Myers, eds. Elections and Democracy in Greater China. By Jeremy Paltiel 936Polo, Anne-Lise. La Nef marrane : essai sur le retour du judaïsme aux portes de l'Occident. Par Sophie Régnière 939Hazony, Yoram. The Jewish State: The Struggle for Israel's Soul. By Neil Caplan and Rueven Shultz 941Embong, Abdul Rahman and Jurgen Rudolph, eds. Southeast Asia into the Twenty First Century: Crisis and Beyond. By Erik M. Kuhonta 943Sidjanski, Dusan. The Federal Future of Europe. From the European Community to the European Union. By Amy Verdun 945Capling, Ann. Australia and the Global Trade System: From Havana to Seattle. By Nobuaki Suyama 946Thompson, John B. Political Scandal: Power and Visibility in the Media Age. By Constantine J. Spiliotes 947Rozell, Mark J. and Clyde Wilcox, eds. The Clinton Scandal and the Future of American Government. By Hans Hacker 949Volkoff, Vladimir. Désinformations par l'image. Par Yves Laberge 952Graber, Doris A. Processing Politics: Learning from Television in the Internet Age. By Terri Susan Fine 952Delacampagne, Christian. Le philosophe et le tyran. Par Francis Dupuis- Déri 954Gaukroger, Stephen. Francis Bacon and the Transformation of Early- Modern Philosophy. By Travis D. Smith 955Grell, Ole Peter and Roy Porter, eds. Toleration in Enlightened Europe. By Jene M. Porter 957Murphy, Andrew R. Conscience and Community: Revisiting Toleration and Religious Dissent in Early Modern England and America. By Mark David Hall 959Todorov, Tzvetan. Frail Happiness: An Essay on Rousseau. By Rosanne Kennedy 960Braybrooke, David. Natural Law Modernized. By John von Heyking 962Munzer, Stephen R., ed. New Essays in the Legal and Political Theory of Property. By Rowan Cruft 964Dallmayr, Fred and José M. Rosales, eds. Beyond Nationalism? Sovereignty and Citizenship. By Josep Costa 966David, Charles-Philippe. La guerre et la paix : Approches contemporaines de la sécurité et la stratégie. Par Jean-Sébastien Rioux 967Deveaux, Monique. Cultural Pluralism and Dilemmas of Justice. By Philip Parvin 970Barry, Brian. Culture and Equality. By Patti Tamara Lenard 972Hampshire, Stuart. Justice is Conflict. By Colin Farrelly 975Miller, David and Sohail H. Hashmi, eds. Boundaries and Justice: Diverse Ethical Perspectives. By Seana Sugrue 976Cohen, Herman J. Intervening in Africa: Superpower Peacemaking in a Troubled Continent. By Carola Weil 978Nye, Joseph S. and John D. Donahue, eds. Governance in a Globalizing World. By William D. Coleman 980Rupert, Mark. Ideologies of Globalization: Contending Visions of a New World Order. By Stephen McBride 981Thomas, Daniel C. The Helsinki Effect: International Norms, Human Rights, and the Demise of Communism. By Morton Winston 982Stevis, Dimitris and Valerie J. Assetto, eds. The International Political Economy of the Environment. By Edward Sankowski 984

A contemporaneidade trouxe consigo a (des/re)construção da noção de identidade, a qual passa da fixidez à fluidez. A partir dessa premissa, o presente artigo visa à análise do processo de construção identitária individual e coletiva a partir da representação literária, tomando como base o conto “O escritor, sua mulher e o gato”, presente no livro O sucesso (2016), de Adriana Lisboa. Busca-se, assim, compreender como a narrativa brasileira contemporânea, tomando como exemplo o conto, tem representado o indivíduo em termos identitários por meio dos trânsitos realizados pelas personagens. Os estudos de Zygmunt Bauman (1996, 2005, 2012) e Stuart Hall (1996, 2005) sobre identidade, mobilidade e globalização servem como referencial do trabalho, cuja análise parte da fluidez identitária do protagonista em sua relação com elementos simbólicos presentes no texto. Como resultado, observa-se que há uma tendência na narrativa brasileira contemporânea em representar indivíduos fluídos, desenraizados de seus espaços de origem, os quais experimentam a mobilidade sob diferentes perspectivas, trazendo consigo as consequências da globalização em termos culturais.